The OncLive COVID-19 condition center page is a comprehensive resource for clinical news and expert insights on how the COVID-19 pandemic has impacted multiple areas of oncology care and practice. This page features news articles, interviews in written and video format, and podcasts encompassing data of patients with COVID-19 and cancer, oncology drugs being tested against the virus, vaccine information for patients with cancer, and more.
March 9th 2023
Treatment with ruxolitinib impaired antibody responses to complete vaccination with the BNT162b2 SARS-CoV-2 vaccine in patients with myelofibrosis or polycythemia vera.
July 8th 2022
May 26th 2022
COVID-19 Mortality Rates Rise With Hospitalization and Rituximab Treatment in MCLMay 6th 2022
The overall mortality rate for patients with mantle cell lymphoma who contract COVID-19 is high, and mortality rates rise significantly in patients who are hospitalized or enter intensive care units, according to findings from a retrospective study that were published in Hemasphere.
COVID-19 Booster Yields Responses After Failure of Initial Vaccine Doses in Prior HCT or CAR T-Cell Therapy Recipients
The administration of a third dose of a SARS-CoV-2 mRNA vaccine yielded seroconversion responses in patients treated with hematopoietic cell transplantation or cellular therapy following initial failure of seroconversion after the first 2 vaccine doses.
COVID-19 Vaccine Elicits Varied Immune Responses in cGVHDApril 27th 2022
Administration of the SARS-CoV-2 vaccine resulted in heterogeneous immune response in patients with chronic graft-vs-host disease (cGVHD), further highlighting concerns about protection against infection or severe COVID-19 disease in this population
CoVac-1 Vaccination Could Prevent Severe COVID-19 in Patients with Cancer and Immunoglobulin DeficiencyApril 12th 2022
CoVac-1, a multi-peptide COVID-19 vaccine, elicited promising T-cell activity and safety in patients with cancer who have disease- or treatment-related immunoglobulin deficiency.
Study Reveals Increased Disparities in Cervical Cancer Screening Linked With COVID-19 Pandemic
Women of all races and ethnicities who were referred to a colposcopy clinic for cervical cancer screening following an abnormal Pap smear during the COVID-19 pandemic had a higher likelihood of not adhering to their appointment compared with appointment data collected prior to the pandemic.
Analysis Reveals Racial Disparities in Telemedicine Use During COVID-19 Pandemic Among Patients With Hematologic Malignancies
Data from a retrospective observational study revealed that White patients with hematologic malignancies in the United States had significantly higher uptake of telemedicine vs Black patients, reflecting disparities that require further exploration.
Third Dose of COVID-19 Vaccine Improves Response in Patients Treated with HCT and Cellular TherapiesMarch 22nd 2022
Muhammad Bilal Abid, MD, MRCP, discusses clinical takeaways regarding the standard use of a third SARS-CoV-2 mRNA vaccine dose among patients treated with hematopoietic cell transplantation, CAR T-cell therapy, and bispecific T-cell engagers.
Prior Rituximab Reduces the Effectiveness of COVID-19 Vaccination in LymphomaFebruary 9th 2022
Treatment with rituximab prior to COVID-19 vaccination nearly halved the number of patients with B-cell non-Hodgkin lymphoma who developed blocking antibodies following COVID-19 vaccination compared with healthy controls.
Overcoming Barriers to Clinical Access in Oncology Care Delivery Requires Multilevel InterventionsJanuary 13th 2022
Christopher S. Lathan, MD, MS, MPH, discusses the lack of dissemination and implementation of evidence-based health care delivery innovations focused on addressing disparities in care.
FDA Grants Emergency Use Authorization to Long-Acting Antibody Combo for COVID-19 Prevention
The long-acting antibody combination of tixagevimab co-packaged with cilgavimab has been granted emergency use authorization in the United States for the pre-exposure prophylaxis of COVID-19.
COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLLDecember 24th 2021
At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.
Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS
Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.
Oncology Drug Regulation Faces an Uncertain FutureDecember 1st 2021
Maurie Markman, MD, discusses how agency leaders should be encouraged to improve regulatory science, include a patient’s perspective in approval decisions, reduce unnecessary bureaucracy and costs associated with the conduct of trials, and accelerate the overall review process for drug approval.
mRNA COVID-19 Vaccines May Decrease Efficacy in Lymphoid MalignanciesNovember 19th 2021
Patients with lymphoid malignancies, especially those who have received recent anti-CD20 antibody therapy, have reduced humoral responses to the mRNA COVID-19 vaccines, and as such, should continue to take precautionary measures against COVID-19 infection irrespective of vaccination status.
Mortality Rate Associated With COVID-19 Breakthrough Cases Remains High in Hematologic MalignanciesNovember 18th 2021
Although mortality rates in patients with hematologic cancers who develop breakthrough COVID-19 cases after vaccination are high, there has been a significant decrease in incidence since vaccines have become available.
Loss of In-Person Patient Interaction is Key Factor in Pandemic-Related Burnout Among OncologistsNovember 17th 2021
Although community oncologists and hematologists were concerned about loss of income during the COVID-19 pandemic, the loss of in-person patient interaction was cited as the key factor impacting their professional satisfaction.
COVID-19 Vaccination Remains Imperative for Patients with CancerNovember 4th 2021
As the COVID-19 pandemic persists, patients with cancer should receive the full vaccination with 1 of the 3 approved COVID-19 vaccines as soon as they are able, according to Steven Ludlow, PharmD, BCOP, BCPS.
CT-Based Imaging Demonstrates Utility for Early COVID-19 Identification in Lung CancerOctober 29th 2021
Routine computed tomography-based imaging scans identified abnormal ground-glass opacities and infiltrates indicative of COVID-19 in patients with lung cancer undergoing radiation therapy, enabling earlier diagnosis, treatment, and risk reducing measures.
COVID-19 Vaccination Strategies Should Consider Infection Risks for CAR T-Cell Therapy RecipientsOctober 28th 2021
Although CAR T-cell therapies have demonstrated unprecedented activity in patients with heavily pretreated relapsed/refractory hematologic malignancies, they are marked by a significant risk of infections and may limit the efficacy of COVID-19 vaccines.
Research Underscores the Need for Serological Testing After COVID-19 Vaccination in Multiple MyelomaOctober 26th 2021
A proportion of patients with multiple myeloma receiving CD38-directed and BCMA-directed therapies had a lack of T-cell responses and an absence of anti–SARS-CoV-2 Spike antibodies following SARS-CoV-2 vaccination, underscoring the need for serological testing after vaccination to identify these patients.